Species differences in the role of excitatory amino acids in experimental parkinsonism

Neuroscience and Biobehavioral Reviews

Volumn 21, Issue 4, 1997, Pages 401-415

  Fornai, F ^a   Vaglini, F ^a   Maggio, R ^a   Bonuccelli, U ^a   Corsini, G U ^b  

^a UNIVERSITY OF PISA   (Italy)

^b Associazione Anni Verdi   (Italy)

Author keywords

Dopamine; Excitatory amino acid; Experimental parkinsonism; Methamphetamine; MPTP; Nigrostriatal pathway; NMDA antagonists

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 6 HYDROXYDOPA; ACETALDEHYDE; DIETHYLDITHIOCARBAMIC ACID; EXCITATORY AMINO ACID; LEVODOPA; METHAMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OXIDOPAMINE;

ARTICLE; DOPAMINERGIC NERVE CELL; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; PARKINSONISM; PATHOGENESIS; PRIORITY JOURNAL;

ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; EXCITATORY AMINO ACIDS; MICE; MPTP POISONING; PARKINSON DISEASE, SECONDARY; SPECIES SPECIFICITY;

EID: 0031006956     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7634(96)00042-5     Document Type: Article

References (156)

1. 1. Aizenman, E.; Harnett, K. A.; Reynolds, I. J., Oxygen free radicals regulate NMDA receptors via a redox modulatory site. Neuron, 5, 841-846 1990.
2. 2. Aizenman, E.; White, W. F.; Loring, R. H.; Rosenberg, P. A., A 3-4-dihydroxyphenylalanine oxidation product is a non-N-methyl-D-aspartate glutamatergic agonist in rat cortical neurons. Neurosci. Lett., 116, 168-171 1990.
3. 3. Aizenman, E.; Boeckman, F. A.; Rosenberg, P. A., Glutathione prevents 2,4,5-trihydroxyphenylalanine excitotoxicity by maintaining it in a reduced, non-active form. Nerosci. Lett., 44, 233-236 1992.
4. 4. Albin, R. L.; Greenamyre, J. T., Alternative excitotoxic hypothesis. Neurology, 42, 733-738 1992.
5. 5. Albin, R. L.; Makowiec, R. L.; Hollingsworth, Z. R.; Dure, L. S.; Penney, J. B.; Young, A. B., Excitatory amino acids binding sites in the basal ganglia of the rat: a quantitative autoradiographic study. Neuroscience, 46, 35-48 1992.
6. 6. Alvord, E. C. Jr; Forno, L. S. Pathology. In: Koller, W. C., ed. Handbook of Parkinson's disease, 2nd ed. New York: Marcel Dekker; 1992:255-284.
7. 7. Barbeau, A.; Dallaire, L.; Buu, N. T.; Veilleux, F.; Boyer, H.; DeLanney, L. E.; Irwin, I.; Langston, E. B.; Langston, J. W., New amphibian models for the study of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci., 36, 1125-1134 1985.
8. 8. Baumgarten, H. G.; Zimmermann, B. Cellular and subcellular targets of neurotoxins: the concept of selective vulnerability. In: Herken, H.; Hucho, F., eds. Selective neurotoxicity. Berlin: Springer-Verlag; 1992:1-27.
9. 9. Beal, M. F., Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol., 31, 119-130 1992.
10. 10. Beal, M. F.; Hyman, B. T.; Koroshetz, W., Do defects in mitochondrial energy metabolism underlie the pathology of Parkinson's disease? Trends Neurosci., 16, 125-131 1993.
11. 11. Bennett, B. A.; Hyde, C. E.; Pecora, J. R.; Clodfelter, J. E., Differing neurotoxic potencies of methamphetamine, mazindol, and cocaine in mesencephalic cultures. J. Neurochem., 60, 444-1452 1993.
12. 12. Biscoe, T. J.; Evans, R. H.; Headley, P. M.; Martin, M. R.; Watkins, J. C., Structure-activity relations of excitatory amino acids on frog and rat spinal neurons. Br. J. Pharmacol., 58, 373-382 1976.
13. 13. Bloem, B. R.; Irwin, I.; Buruma, O. J. S.; Haan, J.; Roos, R. A. C.; Tetrud, J. W.; Langston, J. W., The MPTP model: versatile contribution to the treatment of idiopathic Parkinson's disease. J. Neurol. Sci., 97, 273-293 1990.
14. 14. Bonuccelli, U.; Del Dotto, P.; Piccini, P.; Beghé, F.; Corsini, G. U.; Muratorio, A., Dextromethorphan and Parkinsonism. Lancet, 340, 53 1992.
15. 15. Brouillet, E.; Beal, M. F., NMDA antagonists partially protect against MPTP-induced neurotoxicity in mice. Neuroreport, 4, 387-390 1993.
16. 16. Burns, R. A.; Chiueh, C. C.; Markey, S. P.; Ebert, M. H.; Jacobowicz, D. M.; Kopin, I. J., A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl Acad. Sci. U.S.A., 80, 4546-4550 1983.
17. +. Neurosci. Lett., 117, 129-133 1990.
18. 18. Carlsson, M.; Carlsson, A., Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci., 13, 272-277 1990.
19. 3H)AMPA binding in rat striatum. Neurosci. Lett., 132, 55-58 1991.
20. 20. Chan, P.; DeLanney, L. E.; Irwin, I.; Langston, J. W.; Di Monte, D., Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain. J. Neurochem., 57, 348-351 1991.
21. + elimination in the mouse striatum. J. Pharmacol. Exp. Ther., 267, 1515-1520 1993.
22. 22. Chan, P.; Langston, J. W.; Irwin, I.; DeLanney, L. E.; Di Monte, D. A., 2-deoxyglucose enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced ATP loss in the mouse brain. J. Neurochem., 61, 610-616 1993.
23. 23. Chan, P.; Di Monte, D. A.; Luo, J.-J.; DeLanney, L. E.; Irwin, I.; Langston, J. W., Rapid ATP loss caused by methamphetamine in the mouse striatum: relationship between energy impairment and dopaminergic neurotoxicity. J. Neurochem., 62, 2484-2487 1994.
24. 24. Chiba, K.; Trevor, A.; Castagnoli, N. Jr, Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun., 120, 1228-1232 1984.
25. 25. Chiueh, C. C.; Markey, S. P.; Burns, S. N.; Johannessen, J. N.; Pert, A.; Kopin, I. J., Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat. Eur. J. Pharmacol., 100, 189-194 1984.
26. 26. Chiueh, C. C.; Markey, S. P.; Burns, R. S.; Johannessen, J. N.; Jacobowitz, D. M.; Kopin, I., Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in rat, guinea pig and monkey. Psychopharm. Bull., 20, 548-553 1984.
27. +) sustained exocytosis of endogenous striatal dopamine in vivo. Eur. J. Pharmacol., 183, 1069-1071 1990.
28. + enhances potassium-evoked striatal dopamine release through a omega-conotoxin-insensitive, tetrodotoxin- and nimodipine-sensitive calcium-dependent mechanism. Ann. N.Y. Acad. Sci., 635, 393-396 1991.
29. 29. Choi, D. W., Glutamate neurotoxicity and diseases of the nervous system. Neuron, 1, 623-634 1988.
30. 30. Choi, D. W., Calcium-mediated neurotoxicity: a relationship to specific channel types and role in ischemic damage. Trends Neurosci., 11, 456-469 1988.
31. 31. Close, S. P.; Elliot, P. J.; Hayes, A. G.; Marriott, A. S., Effects of classical and novel agent in a MPTP-induced reversible model of Parkinson's disease. Psychopharmacology, 102, 295-300 1990.
32. 32. Collins, R. C., Neurotoxins and the selective vulnerability of the brain. In: Jenner, P., ed., Neurotoxins and their pharmacological implications. New York: Raven; 1987:1-17.
33. 33. Corsini, G. U.; Pintus, S.; Chiueh, C. C.; Weiss, J. F.; Kopin, I. J., 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by pre-treatment with diethyldithiocarbamate. Eur. J. Pharmacol., 119, 127-128 1985.
34. 34. Corsini, G. U.; Zuddas, A.; Bonuccelli, U.; Schinelli, S.; Kopin, I. J., 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by ethanol or acetaldehyde. Life Sci., 40, 827-832 1985.
35. 35. Corsini, G. U.; Vaglini, F.; Fornai, F.; Saginario, A.; Zuddas, A., (+ )MK-801 prevents dopaminergic perikaria damage in MPTP and acetaldehyde-treated mice. Posters Neurosci., 1, 33-36 1991.
36. 36. Corsini, G. U.; Vaglini, F.; Zuddas, A.; Fornai, F.; Saginario, A.; Scalori, V. Excitatory amino acids, MPTP toxicity and dopaminergic nerve cell death in Parkinson's disease. In: Agid, Y., ed. Current trends in the treatment of Parkinson's disease. London: John Libbey and Company Ltd; 1992:5-17.
37. 37. Cotman, C. W.; Monaghan, D. T.; Ottersen, O. P.; Storm-Mathisen, J., Anatomical organization of excitatory amino acid receptors and their pathways. Trends Neurosci., 10, 273-280 1987.
38. 38. Coyle, J. Y.; Puttfarcken, P., Oxidative stress, glutamate, and neurodegenerative disorders. Science, 262, 689-695 1993.
39. 39. Crossman, A. R.; Peggs, D.; Boyce, S.; Luquin, M. R.; Sambrook, M. A., Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey. Neuropharmacology, 28, 1271-1273 1989.
40. 40. Davis, C. G.; Williams, A. C.; Markey, S. P.; Ebert, M. H.; Calne, E. D.; Reichert, C. M.; Kopin, I. J., Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiat. Res., 1, 249-254 1979.
41. 41. Denton, T.; Howard, B. D., A dopaminergic cell line variant resistant to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Neurochem., 49, 622-629 1987.
42. +) cause rapid ATP depletion in isolated hepatocytes. Biochem. Biophys. Res. Commun., 137, 310-315 1986.
43. 43. Di Monte, D. A.; Wu, E. Y.; Irwin, I.; DeLanney, L. E.; Langston, J. W., Production and disposition of 1-methyl-4-phenylopyridinium in primary cultures of mouse astrocytes. Glia, 5, 48-55 1992.
44. 44. Driscoll, B. F.; Law, M. J.; Crane, A. M., Cell damage associated with changing the medium of mesencephalic cultures in serum-free medium is mediated via N-methyl-D-aspartate receptors. J. Neurochem., 56, 1201-1206 1991.
45. 45. Ellison, G.; Eison, M. S.; Huberman, H. S.; Daniel, F., Long-term changes in dopaminergic innervation of caudate nucleus after continuous amphetamine administration. Science, 201, 276-278 1978.
46. 46. Fahn, S.; Cohen, G., The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neurol., 32, 804-812 1992.
47. 47. Finiels-Marlier, F.; Marini, A. M.; Williams, P.; Paul, S. M., The N-methyl-D-aspartate antagonist MK-801 fails to protect dopaminergic neurons from 1-methyl-4-phenylpyridinium neurotoxicity in vitro. J. Neurochem., 60, 1968-1971 1993.
48. 48. Fonnum, F., Glutamate: a neurotransmitter in the mammalian brain. J. Neurochem., 42, 1-11 1984.
49. 49. Fornai, F.; Vaglini, F.; Maggio, R.; Bonuccelli, U.; Corsini, G. U., Excitatory amino acids and MPTP toxicity. Adv. Neurol., 69, 167-176 1996.
50. +) together with 6-hydroxydopamine or dopamine stimulates calcium release from mitochondria. FEBS Lett., 198, 99-102 1986.
51. 51. Fuller, R. W.; Heimrick-Luecke, S. K.; Ornstein, P. L., Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist. Neuropharmacology, 31, 1027-1032 1992.
52. 52. Garruto, R. M., Pacific paradigms of environmentally-induced neurological disorders: clinical, epidemiological and molecular perspectives. Neurotoxicology, 12, 347-378 1991.
53. 53. Gibb, J. W.; Kogan, K. F., Influence of dopamine synthesis on methamphetamine-induced changes in striatal and adrenal tyrosine hydroxylase. Naunyn Schmiedeberg's Arch. Pharmacol., 310, 185-187 1979.
54. 54. Giovanni, A.; Sieber, B.-A.; Heikkila, R. E.; Sonsalla, P. K., Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice. J. Pharmacol. Exp. Ther., 257, 691-697 1991.
55. 55. Giovanni, A.; Sieber, B.-A.; Heikkila, R. E.; Sonsalla, P. K., Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Pat 1: Systemic administration. J. Pharmacol. Exp. Ther., 270, 1000-1007 1994.
56. 56. Giovanni, A.; Sonsalla, P. K.; Heikkila, R. E., Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium. J. Pharmacol. Exp. Ther., 270, 1008-1014 1994.
57. 57. Globus, M. Y. T.; Ginsberg, M. D.; Dietrich, W. D.; Busto, R.; Sheinberg, P., Substantia nigra lesions protect against ischemic damage in the striatum. Neurosci. Lett., 80, 251-256 1987.
58. 58. Hallman, H.; Olson, L.; Jonsson, G., Neurotoxicity of the meperidine analog N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurons in the mouse. Eur. J. Pharmacol., 97, 133-136 1984.
59. 59. Harik, S. I.; Schmidley, J. W.; Iacofano, L. A.; Blue, P.; Arora, P. K.; Sayre, L. M., On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: the effect of perinigral infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, its metabolite and their analogs in the rat. J. Pharmacol. Exp. Ther., 241, 669-676 1987.
60. +) induces NADH-dependent superoxide formation, and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem. Biophys. Res. Commun., 170, 1049-1055 1990.
61. 61. Heikkila, R. E.; Hess, A.; Duvosin, R. C., Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Science, 224, 1451-1453 1984.
62. 62. Heikkila, R. E.; Manzino, L.; Cabbat, F. S.; Duvoisin, R. C., Protection against the dopaminergic toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature, 311, 467-469 1984.
63. 63. Henneberry, R. C.; Novelli, A.; Cox, J. A.; Lysko, P. G., Neurotoxicity of the N-methyl-D-aspartate receptor in energy-compromised neurons. An hypothesis for cell death in aging and disease. Ann. N. Y. Acad. Sci., 568, 225-233 1989.
64. + within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study. Neuroscience, 40, 133-158 1991.
65. 65. Javitch, J. A.; D'Amato, R. J.; Strittmatter, S. M.; Snyder, S. H., Parkinsonism-inducing neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Uptake of the metabolite N-methyl-4-phenyldropyridine by dopamine neurons explains selective toxicity. Proc. Natl Acad. Sci. U.S.A., 82, 2173-2177 1985.
66. +) within catecholaminergic neurons. Neurotoxicology, 12, 285-302 1991.
67. +) induces oxidative stress in the rodent. Life Sci., 38, 743-749 1986.
68. 68. Johansen, F. F.; Jorgensen, M. B.; Diemer, N. H., Ischemic CA-1 pyramidal cell loss is prevented by preischemic colchicine destruction of dentate gyrus granule cells. Brain Res., 377, 344-347 1986.
69. 69. Jonsson, G.; Nwanze, E.; Luthmann, J.; Sundstrom, E., Effects of MPTP and its pyridinium metabolites on monoamine uptake and on central catecholamine neurons in mice. Acta Physiol. Scand., 128, 187-194 1986.
70. 70. Kass, I. S.; Lipton, P., Mechanisms involved in irreversible anoxic damage to the in vitro rat hippocampal slice. J. Physiol., 332, 459-472 1982.
71. 71. Kordower, J. H.; Felten, S. Y.; Felten, D. L.; Gash, D. M. Behavioral sequelae following MPTP administration in mice. In: Markey, S. P., Castagnoli, N. Jr; Trevor, A. J.; Kopin, I. J., eds. MPTP: A neurotoxin producing a Parkinsonian syndrom. Orlando, FL: Academic Press; 1986:413-417.
72. 72. Krebs, M. O.; Desce, J. M.; Kemel, M. L.; Gauchy, C.; Godeheu, G.; Cheramy, A.; Glowinski, J., Glutamatergic control of dopamine release in rat striatum: evidence for N-methyl-D-aspartate receptors on dopaminergic nerve terminal. J. Neurochem., 56, 81-85 1991.
73. 73. Kupsch, A.; Loshmann, P. A.; Sauer, H.; Arnold, G.; Renner, P.; Pufal, D.; Burg, M.; Wachtel, H.; ten Bruggencate, G.; Oertel, W. H., Do NMDA receptor antagonists protect against MPTP toxicity? Biochemical and immunocytochemical analysis in black mice. Brain Res., 592, 74-83 1992.
74. 74. Lafon-Cazal, M.; Pietri, S.; Culcasi, M.; Bockaert, J., NMDA-dependent superoxide production and neurotoxicity. Nature, 364, 535-537 1993.
75. 75. Lange, K. W.; Loschmann, P. A.; Sofic, E.; Burg, M.; Horowski, R.; Kalveram, K. T.; Wachtel, H.; Riederer, P., The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates. Naunyn Schmiedeberg's Arch. Pharmacol., 348, 586-592 1993.
76. 76. Langston, J. W.; Ballard, P.; Tetrud, J. W.; Irwin, I., Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science, 219, 979-980 1983.
77. 77. Langston, J. W.; Irwin, I.; Langston, E. B., Pargyline prevents MPTP-induced parkinsonism in primates. Science, 225, 1480-1482 1984.
78. +): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci. Lett., 48, 87-92 1984.
79. 79. Lestienne, P.; Nelson, I.; Riederer, P.; Jellinger, K.; Reichmann, H., Normal mitochondrial genome in brain from patients with Parkinson's disease and complex I defect. J. Neurochem., 55, 1810-1812 1990.
80. 80. Lipton, S. A.; Rosenberg, P. A., Excitatory amino acids as a final common pathway for neurologic disorders. New Engl. J. Med., 330, 613-622 1994.
81. 81. Lucas, D. R.; Newhouse, J. P., The toxic effect of sodium L-glutamate on the inner layers of the retina. Arch. Ophthalmol., 58, 193-201 1957.
82. 82. Marini, A. M.; Paul, S. M., N-methyl-D-aspartate-mediated neuroprotection in cerebellar granule cells requires new RNA and protein synthesis. Proc. Natl Acad. Sci. U.S.A., 89, 6555-6559 1992.
83. 83. Markey, S. P.; Johannessen, J. N.; Chiueh, C. C.; Burns, R. S.; Herkenham, M. A., Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature, 311, 464-467 1984.
84. 84. Marshall, J. F.; O'Dell, S. J.; Weihmuller, F. B., Dopamine-glutamate interactions in methamphetamine-induced neurotoxicity. J. Neural Transm. (Gen. Sec.), 91, 241-254 1993.
85. 85. Melamed, E.; Pikarski, E.; Goldberg, A.; Rosenthal, J.; Uzzan, A.; Conforti, N., Effect of serotonergic, corticostriatal and kainic acid lesions on the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice. Brain Res., 399, 178-180 1986.
86. 86. Melamed, E.; Martinovits, G.; Pikarsky, E.; Rosenthal, J.; Uzzan, A., Diphenylhydantoin and phenobarbital suppress the dopaminergic neurotoxicity of MPTP in mice. Eur J. Pharmacol., 128, 255-257 1986.
87. 87. Mereu, G.; Costa, E.; Armstrong, D. M.; Vicini, S., Glutamate receptors subtypes mediate excitatory synaptic currents of dopamine neurons in midbrain slices. J. Neurosci., 11, 1359-1366 1991.
88. +) in rat dissociated mesencephalic cultures. Brain Res., 597, 233-240 1992.
89. 89. Miller, D. B.; Reinhard, J. F.; Daniels, A. J.; O'Callaghan, J. P., Diethyldithiocarbamate potentiates the neurotoxicity of in vivo 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine and of in vitro 1-methyl-4-phenylpyridinium. J. Neurochem., 57, 541-549 1991.
90. 90. Montastruc, J. L.; Rascol, O.; Senard, J. M.; Rascol, A., A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease. J. Neurol. Neurosurg. Psychiatr., 55, 630-631 1992.
91. 91. Muraki, A.; Koyama, T.; Nakayama, M.; Ohmori, T.; Yamashita, I., MK-801, a non-competitive antagonist of NMDA receptor prevents methamphetamine-induced decrease of striatal dopamine uptake sites in the rat striatum. Neurosci. Lett., 136, 39-42 1992.
92. 92. Nash, J. F.; Yamamoto, B. K., Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine. Brain Res., 581, 237-243 1992.
93. 93. Nicholls, D.; Atwell, D., The release and uptake of excitatory amino acids. Trends Pharmacol. Sci., 11, 462-468 1990.
94. 94. Nicklas, W. J.; Vyas, I.; Heikkila, R. E., Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci., 36, 2503-2508 1985.
95. 95. O'Dell, S. J.; Weihmuller, F. B.; Marshall, J. F., Multiple methamphetamine injections induce marked increases in extracellular striatal dopamine which correlate with subsequent neurotoxicity. Brain Res., 564, 256-260 1991.
96. 96. O'Dell, S. J.; Weihmuller, F. B.; Marshall, J. F., MK-801 prevents methamphetamine-induced striatal dopamine damage and reduces extracellular dopamine overflow. In: Neurotoxins and neurodegenerative disease. Ann. N. Y. Acad. Sci., 648, 317-319 1992.
97. 97. Olney, J. W. Excitotoxic mechanisms of neurotoxicity. In: Spencer P. S.; Shaumberg, H. H., eds. Experimental and clinical neurotoxicology. Baltimore: Williams and Wilkins; 1980:272-294.
98. 98. Olney, J. W., Excitotoxic amino acids and neuropsychiatric disorders. A. Rev. Pharmacol. Toxicol., 30, 47-71 1990.
99. 99. Olney, J. W.; de Gubareff, T., Glutamate neurotoxicity and Huntington's chorea. Nature, 271, 557-559 1978.
100. 100. Olney, J. W.; Zorumsky, C. F.; Stewart, G. R.; Price, M. T.; Wang, G.; Labruyere, J., Excitotoxicity of L-DOPA and 6-OH-DOPA; implications for Parkinson's and Huntington's disease. Exp. Neurol., 108, 269-272 1990.
101. 101. Onodera, H.; Sato, G.; Kogure, K., Lesions to Shaffer collaterals prevent ischemic death of CA1 pyramidal cells. Neurosci. Lett., 68, 169-174 1986.
102. 102. Ossowska, K., The role of excitatory amino acids in experimental models of Parkinson's disease. J. Neural. Transm. (P-D Sect)., 8, 39-71 1994.
103. 103. Overton, P.; Clark, D., N-Methyl-D-aspartate increases the excitability of nigrostriatal dopamine terminals. Eut. J. Pharmacol., 201, 117-120 1991.
104. 104. Perry, T. L.; Godin, D. V.; Hansen, S., Parkinson's disease: a disorder due to nigral glutathione deficiency?. Neurosci. Lett., 33, 305-310 1982.
105. 105. Perry, T. L.; Yong, V. W.; Clavier, R. M.; Jones, K.; Wright, J. M.; Foulks, J. G.; Wall, R. A., Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Neurosci. Lett., 60, 109-114 1985.
106. 106. Piallat, B.; Bernazzouz, A.; Bressand, K.; Vercueil, L.; Benabid, A. L., Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection. Soc. Neurosci. Abs., 230, 5 1995.
107. 107. Pileblad, E.; Carlsson, A., Catecholamine-uptake inhibitors prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse brain. Neuropharmacology, 24, 689-692 1985.
108. 108. Ramsay, R. R.; Singer, T. P., Energy-dependent uptake of 1-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J. Biol. Chem., 261, 7885-7887 1986.
109. 109. Rapisardi, S. C.; Warrington, V. O. P.; Wilson, J. S., Effects of MPTP on fine structure of neurons in substantia nigra of dogs. Brain Res., 512, 147-154 1990.
110. 110. Ricaurte, G. A.; Langston, J. W.; DeLanney, L. E.; Irwin, I.; Brooks, J. D., Dopamine uptake blockers protect against the dopamine depleting effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse striatum. Neurosci. Lett., 59, 259-264 1985.
111. 111. Ricaurte, G. A.; Langston, J. W.; DeLanney, L. E.; Irwin, I.; Peroutka, S. J.; Forno, L. S., Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine: a neurochemical and morphological reassessment. Brain Res., 376, 117-124 1986.
112. +. Eur. J. Pharmacol., 126, 345-346 1986.
113. +-induced efflux of DA and lactate from rat striatum have similar time courses as shown by in vivo brain dialysis. J. Pharmacol. Exp. Ther., 245, 858-866 1988.
114. 114. Rosenberg, P. A.; Loring, R.; Xie, Y.; Zaleskas, V.; Aizenman, E., 2,3,5, Trihydroxyphenylalanine in solution forms a non-N-methyl-D-aspartate glutamatergic agonist and neurotoxin. Proc. Natl Acad. Sci. U.S.A., 88, 4865-4869 1991.
115. 115. Rothman, S. M., Synaptic activity mediates death of hypoxic neurons. Science, 220, 536-537 1983.
116. 116. Rothman, S. M., Synaptic release of excitatory amino acid neurotransmitter mediates anoxic neuronal death. J. Neurosci., 4, 1884-1891 1984.
117. 117. Rupniak, N. M. J.; Boyce, S.; Steventon, M. J.; Iversen, S. D.; Marsden, C. D., Dystonia induced by combined treatment with L-dopa and MK-801 in parkinsonian monkeys. Ann. Neurol., 32, 103-105 1992.
118. +). Naunyn Schmiedebergs Arch. Pharmacol., 346, 158-165 1992.
119. 119. Sachs, C.; Jonsson, G., Mechanism of action of 6-hydroxydopamine. Biochem. Pharmacol., 24, 1-8 1975.
120. 120. Sanchez-Ramos, J. R.; Michel, P.; Weiner, W. J.; Hefti, F., Selective destruction of cultured dopaminergic neurons from rat mesencephalon by 1-methyl-4-phenylpyridinium: cytochemical and morphological evidence. J. Neurochem., 50, 1934-1944 1988.
121. 121. Schapira, A. H. V.; Cooper, J. M.; Dexter, D.; Clark, J. B.; Jenner, P.; Marsden, C. D., Mitochondrial complex 1 deficiency in Parkinson's disease. J. Neurochem., 54, 823-827 1990.
122. 122. Schneider, J. S.; Juviler, A.; Markham, C. H., Production of a Parkinson-like syndrome in the cat with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): behavior, histology and biochemistry. Exp. Neurol., 91, 293-307 1986.
123. 123. Scotchner, K. P.; Irwin, I.; DeLanney, L. E.; Langston, J. W.; Di Monte, D., Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion on ATP levels of mouse brain synaptosomes. J. Neurochem., 54, 1295-1301 1990.
124. 124. Seiden, L. S.; Fischman, M. W.; Shuster, C. R., Long-term methamphetamine-induced changes in brain catecholamines in tolerant rhesus monkeys. Drug Alcohol Depend., 1, 215-219 1975.
125. 125. Siesjo, B. K., Cell damage in the brain: a speculative synthesis. J. Cereb. Blood Flow Metab., 1, 155-185 1981.
126. 126. Simon, R. P.; Swan, J. H.; Griffiths, T.; Meldrum, B. S., Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science, 226, 850-852 1984.
127. 127. Sloviter, R. S., "Epileptic" brain damage in rats induced by sustained electrical stimulation of the perforant path. I. Acute electrophysiological and light microscopic studies. Brain Res. Bull., 10, 675-697 1983.
128. 128. Sloviter, R. S.; Sollas, A. L.; Dean, E.; Dichter, M. A., Immunocytochemical localization of 65 and 67 kDa glutamic acid decarboxylase (GAD) and GABA-like immunoreactivities in the rat hippocampal formation; GAD 67 and GABA are present in normal dentate granule cells and are rapidly induced by afferent stimulation, kainic acid or pilocarpine. Soc. Neurosci. Abs., 771, 2 1995.
129. 129. Sonsalla, P. K.; Nicklas, W. J.; Heikkila, R. E., Role for excitatory amino acids in metamphetamine-induced nigrostriatal dopaminergic toxicity. Science, 243, 398-400 1989.
130. 130. Sonsalla, P. K.; Nicklas, W. J. MPTP and animal models of Parkinson's disease. In: Koller, W. C., ed. Handbook of Parkinson's disease. 2nd ed. New York: Marcel Dekker; 1992:319-340.
131. 131. Sonsalla, P. K.; Riordan, D. E.; Heikkila, R. E., Competitive and noncompetitive antagonists at N-methyl-D-aspartate receptors protect against methamphetamine-induced dopaminergic damage in mice. J. Pharmacol. Exp. Ther., 256, 506-512 1991.
132. 132. Sonsalla, P. K.; Giovanni, A.; Sieber, B.-A.; Delle Donne, K.; Manzino, L., Characteristics of dopaminergic neurotoxicity produced by MPTP and methamphetamine. In: Neurotoxins and neurodegenerative disease. Ann. N.Y. Acad. Sci., 648, 229-238 1992.
133. 133. Sonsalla, P. K.; Zeevalk, G. D.; Manzino, L.; Giovanni, A.; Nicklas, W. J., MK-801 fails to protect against the dopaminergic neuropathology produced by systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice or intranigral 1-methyl-4-phenylpyridinium in rats. J. Neurochem., 58, 1979-1982 1992.
134. 134. Storey, E.; Hyman, B. T.; Jenkins, B.; Brouillet, E.; Miller, J. M.; Rosen, B. R.; Beal, M. F., 1-Methyl-4-phenylpyridinium produces excitotoxic lesion in rat striatum as a result of impairment of oxidative metabolism. J. Neurochem., 58, 1975-1978 1992.
135. 135. Sundstrom, E.; Jonsson, G., Pharmacological interference with the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in the mouse. Eur. J. Pharmacol., 110, 293-299 1985.
136. +) in mice. Eur. J. Pharmacol., 131, 289-292 1986.
137. 137. Sundstrom, E.; Henriksson, B. G.; Mohammed, A. H.; Souverbie, F. MPTP-treated mice: a useful model for Parkinson's disease? In: Woodruff, M. L.; Nonneman, A. J., eds. Toxin-induced models of neurological disorders. New York: Plenum Press; 1994:121-137.
138. 138. Tabatabaei, A.; Perry, T. L.; Hansen, S.; Krieger, C., Partial protective effects of MK-801 on MPTP-induced reduction of striatal dopamine in rats. Neurosci. Lett., 141, 192-194 1992.
139. 139. Tallaksen-Green, S. J.; Wiley, R. G.; Albin, R. L., Localization of striatal excitatory amino acids binding site subtypes to striatonigral projection neurons. Brain Res., 594, 165-170 1992.
140. 140. Tanner, C. M. Epidemiological clues to the cause of Parkinson's disease. In: Fahn, S.; Marsden, C. D., eds. Movement disorders. Vol. 3. Oxford: Butterworth-Heinemann; 1994:124-146.
141. 141. Taylor, J. R.; Elsworth, J. D.; Roth, R. H.; Sladek, J. R.; Redmond, D. E. Behavioral effects of MPTP administration in the Vervet monkey: a primate model of Parkinson's disease. In: Woodruff, M. L.; Nonneman, A. J., eds. Toxin-induced models of neurological disorders. New York: Plenum Press; 1994:139-174.
142. 142. Tetrud, J. W.; Langston, J. W., Effects of L-deprenyl (selegiline) on the natural history of Parkinson's disease. Science, 245, 519-522 1989.
143. 143. The Parkinson's Study Group. Effect of deprenyl on th progression and disability in early Parkinson's disease. N. Engl. J. Med. 20:1364-1371; 1989.
144. 144. Tipton, K. F.; Singer, T. P., Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem., 61, 1191-1206 1993.
145. + neurotoxicity by N-methyl-D-aspartate antagonists. Nature, 349, 414-418 1991.
146. 146. Vaglini, F.; Fascetti, F.; Fornai, F.; Maggio, R.; Corsini, G. U., (+)MK-801 prevents the DDC-induced enhancement of MPTP toxicity in mice. Brain Res., 668, 194-203 1994.
147. 147. Vaglini, F.; Pardini, C.; Maggio, R.; Corsini, G. U., Role of excitatory amino-acids in diethyldithiocarbamate-induced cell death in mesencephalic cultures. Brain Res., 674, 127-132 1995.
148. 148. Vogt, C.; Vogt, O., Sitz und Wesen der Krankheiten im Lichte der topistischen Hirnforshung und des Variierens der Tiere. J. Psychol. Neurol., 47, 237-457 1937.
149. 149. Wagner, G. C.; Ricaurte, G. A.; Seiden, L. S.; Schuster, C. R.; Miller, R. J.; Westley, J., Long-lasting depletion of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res., 181, 151-160 1980.
150. 150. Willis, G. L.; Donnan, G. A., Histochemical, biochemical and behavioral consequences of MPTP treatment in C-57 black mice. Brain Res., 402, 269-274 1987.
151. 151. Willis, G. L.; Donnan, G. A., Motor function in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse. J. Neurol. Sci., 77, 185-191 1987.
152. 152. Yurek, D. M.; Deutch, A. Y.; Roth, R. H.; Sladek, J. R. Jr, Morphological, neurochemical and behavioral characterizations associated with the combined treatment of diethyldithiocarbamate and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Brain Res., 497, 250-259 1989.
153. 153. Zuddas, A.; Corsini, G. U.; Schinelli, S.; Johannessen, J. N.; di Porzio, U.; Kopin, I. J., MPTP treatment combined with ethanol or acetaldehyde selectively destroys dopaminergic neurons in mouse substantia nigra. Brain Res., 501, 1-10 1989.
154. + neurotoxicity and delays its elimination from the rat striatum. Brain Res., 501, 11-22 1989.
155. 155. Zuddas, A.; Oberto, G.; Vaglini, F.; Fascetti, F.; Fornai, F.; Corsini, G. U., MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in primates. J. Neurochem., 59, 733-739 1992.
156. + is accumulated in nigrostriatal dopaminergic terminals but it is not neurotoxic: a model of neural resistance to MPTP toxicity. Exp. Neurol., 127, 54-61 1994.